Literature DB >> 6358997

Effect of Sialor in treatment of xerostomia in Sjögren's syndrome.

J B Epstein, W E Decoteau, A Wilkinson.   

Abstract

Sialor, a sialogogue, was studied in a double-blind crossover trial in patients with autoimmune exocrinopathy (Sjögren's syndrome). Sialor appears to frequently alleviate the symptoms of xerostomia and increase salivary flow rate, and it is rarely associated with side effects. Sialor is useful in management of xerostomia in patients with Sjögren's syndrome and may also be of value in the treatment of xerophthalmia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6358997     DOI: 10.1016/0030-4220(83)90096-8

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  5 in total

Review 1.  Targeting NRF2 signaling for cancer chemoprevention.

Authors:  Mi-Kyoung Kwak; Thomas W Kensler
Journal:  Toxicol Appl Pharmacol       Date:  2009-09-02       Impact factor: 4.219

Review 2.  Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome.

Authors:  W A van der Reijden; A Vissink; E C Veerman; A V Amerongen
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

Review 3.  Dithiolethiones for cancer chemoprevention: where do we stand?

Authors:  Yuesheng Zhang; Rex Munday
Journal:  Mol Cancer Ther       Date:  2008-11       Impact factor: 6.261

Review 4.  Salivary Secretory Disorders, Inducing Drugs, and Clinical Management.

Authors:  Jaume Miranda-Rius; Lluís Brunet-Llobet; Eduard Lahor-Soler; Magí Farré
Journal:  Int J Med Sci       Date:  2015-09-22       Impact factor: 3.738

5.  Anethole Dithiolethione Increases Glutathione in Kidney by Inhibiting γ-Glutamyltranspeptidase: Biochemical Interpretation and Pharmacological Consequences.

Authors:  Daniela Giustarini; Federico Galvagni; Isabella Dalle-Donne; Aldo Milzani; Monica Lucattelli; Giovanna De Cunto; Desirée Bartolini; Francesco Galli; Annalisa Santucci; Ranieri Rossi
Journal:  Oxid Med Cell Longev       Date:  2020-09-28       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.